AFM 11

Drug Profile

AFM 11

Alternative Names: AFM 11

Latest Information Update: 23 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Affimed Therapeutics
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action CD19 antigen modulators; CD3 antigen modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-Hodgkin's lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma
  • Preclinical Precursor cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 01 Mar 2018 Affimed Therapeutics has issued patents for AFM 11 in Australia, Canada, Europe, Japan and USA, and pending patents in Australia, Brazil, Canada, China, Europe, Japan, Mexico, Russia and USA
  • 03 Nov 2016 Phase-I clinical trials in Non-Hodgkin's lymphoma (Second-line therapy or greater) in USA (IV)
  • 01 Sep 2016 Phase-I clinical trials in Precursor B-cell lymphoblastic leukaemia-lymphoma (Second-line therapy or greater) in Austria (IV) after September 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top